Femasys Debuts FemaSeed Complete for 40,000 OB/GYNs, Expanding Market Access
Femasys launched FemaSeed Complete on April 22, 2026 at ACOG, enabling OB/GYNs to perform intratubal insemination with built-in sperm prep in-office. Leveraging 40,000 OB/GYNs versus fewer than 2,000 specialists to address care gaps for 10 million infertile US women, the launch widens the market and may boost revenues.
1. Commercial Launch of FemaSeed Complete
On April 22, 2026 at ACOG 2026 in Washington, D.C., Femasys introduced FemaSeed Complete, its first comprehensive in-office fertility solution. The system integrates directional intratubal insemination with FemSperm sperm preparation into a single OB/GYN office visit, eliminating referrals and external lab processing.
2. Addressable Market Expansion
With over 40,000 OB/GYNs in the US compared to fewer than 2,000 fertility specialists, FemaSeed Complete targets earlier intervention for an estimated 10 million infertile women. By placing first-line treatment in routine gynecology practices, Femasys expects to expand patient access and capture a larger share of the fertility market.
3. Clinical Efficacy and Adoption Potential
Published trial data showed FemaSeed more than doubled pregnancy rates over traditional intrauterine insemination while maintaining a comparable safety profile. High patient and practitioner satisfaction in these studies underpins Femasys’s projections for rapid uptake within OB/GYN settings.
4. Conference Showcase and Next Steps
Femasys will demonstrate its full reproductive health portfolio, including FemBloc and FemVue, at booth #524 from May 1–3. The company plans to leverage feedback from attendees to refine training programs and accelerate commercial roll-out.